Table 2.
Univariate and multivariate Cox’s regression analyses of the gene signature in two independent cohorts.
| Variables | Patients (N) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| CGGA | ||||||
| Age | <= 49/ > 49 | 73/64 | 1.00 (0.99–1.02) | 5.76e-01 | 0.99 (0.96–1.02) | 4.06e-01 |
| Gender | Female/Male | 47/90 | 1.22 (0.79–1.88) | 3.75e-01 | 1.59 (0.88–2.86) | 1.23e-01 |
| Radiation therapy | No/Yes | 44/79 | 0.41 (0.26–0.66) | 1.85e-04 | 0.42 (0.25–0.69) | 7.13e-04 |
| Chemotherapy | No/Yes | 41/82 | 0.34 (0.21–0.53) | 2.30e-06 | 0.35 (0.20–0.59) | 8.50e-05 |
| IDH1 mutation | No/Yes | 104/33 | 0.64 (0.38–1.07) | 8.57e-02 | 1.24 (0.54–2.83) | 6.16e-01 |
| TP53 mutation | No/Yes | 62/75 | 0.70 (0.46–1.05) | 8.64e-02 | 0.87 (0.54–1.41) | 5.72e-01 |
| EGFR mutation | No/Yes | 101/36 | 0.74 (0.46–1.21) | 2.34e-01 | 0.57 (0.31–1.03) | 6.64e-02 |
| ATRX mutation | No/Yes | 125/12 | 0.79 (0.38–1.63) | 5.17e-01 | 0.76 (0.26–2.28) | 6.28e-01 |
| EZH2 mutation | No/Yes | 115/22 | 1.13 (0.65–1.98) | 6.68e-01 | 1.57 (0.81–3.06) | 1.84e-01 |
| MGMT expression | Low/High | 69/68 | 1.37 (1.12–1.68) | 2.19E-03 | 1.23 (0.94–1.62) | 1.30E-01 |
| Risk score | Low/High | 69/68 | 2.60 (1.68–4.03) | 1.82e-05 | 2.40 (1.42–4.06) | 1.11e-03 |
| TCGA | ||||||
| Age | <= 60/ > 60 | 80/78 | 1.03 (1.01–1.04) | 1.26e-03 | 1.01 (0.99–1.03) | 2.33e-01 |
| Gender | Female/Male | 56/102 | 0.95 (0.65–1.41) | 8.08e-01 | 1.22 (0.77–1.95) | 4.03e-01 |
| Radiation therapy | No/Yes | 21/130 | 0.16 (0.09–0.26) | 1.34e-12 | 0.12 (0.06–0.23) | 7.76e-11 |
| MGMT expression | Low/High | 79/79 | 1.20 (1.01–1.43) | 3.81E-02 | 1.26 (1.05–1.51) | 1.10E-02 |
| Risk score | Low/High | 81/77 | 1.98 (1.34–2.91) | 5.56e-04 | 1.70 (1.10–2.63) | 1.73e-02 |